NECLIFE11.90

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹231 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation60.762.422.8
+ Finance Costs87.174.636.1
+ Interest Income-12.4-1.9-7.0
+ Dividend Income0.00.0-0.0
+ Other Non-cash Items0.91.60.0
+ Other — Cash Effects are Investing / Financing-0.2-0.0203.7
+ Other Reconciling Items-0.50.8-700.9
Changes in Working Capital
+ Inventories-28.5146.3232.9
+ Trade Receivables — Current-99.633.716.6
+ Trade Receivables — Non-current-1.7-0.2299.3
+ Other Financial Assets — Current32.00.1-56.7
+ Other Financial Assets — Non-current-0.9-0.40.8
+ Other Current Assets53.9-8.8112.2
+ Other Non-current Assets0.0-0.11.6
+ Trade Payables — Current100.918.5-341.7
+ Other Financial Liabilities — Current4.411.0-50.4
+ Other Current Liabilities8.4-8.1-8.1
+ Other Non-current Liabilities-0.0-0.0-0.7
+ Provisions — Current0.40.7-2.9
+ Provisions — Non-current1.50.8-18.6
Cash from Operating Activities
Profit Before Tax (per I/S)18.3-161.5-87.9-25.5
+ Total Adjustments (incl. Working Capital)206.4331.0-260.8
Cash from Operations (pre-tax)224.7169.4-348.7
Cash from Operating Activities224.7169.4-348.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)29.443.812.3
+ Disp of Fixed Assets0.00.020.5
+ Acq of Investment Property0.00.0398.9
+ Disp of Investment Property0.00.0334.4
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing12.41.57.0
+ Other Inflows / (Outflows) — Investing0.00.41,257.5
Cash from Investing Activities-17.0-41.91,208.1
Cash from Financing Activities
+ Payments for Other Equity Instruments0.00.081.0
+ Repayment of Borrowings118.753.3648.8
+ Payment of Lease Liabilities0.00.20.6
+ Payment of Finance Lease Liabilities-0.4
+ Interest Paid87.174.636.1
Cash from Financing Activities-205.4-128.1-766.5
Net Changes in Cash (pre-FX)2.2-0.692.9
Net Changes in Cash2.2-0.692.9
Closing Cash19.8
Reference Items
EBITDA153.1-26.5-60.7-89.2
EBITDA Margin %9.08-1.58-1,779.89
Free Cash Flow (CFO − Capex)195.3125.6-361.0-361.0
Free Cash Flow to Equity-2.4-979.1
Free Cash Flow per Basic Share10.056.47-18.58-18.58
Cash Flow to Net Income44.99-1.491.19
Cash Paid for Interest87.174.636.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.